40 assets in Wilms Tumor

Therapeutic assets addressing Wilms Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Wilms Tumor	Children's National Research Institute	P2	BB (68)
(+)-Vincristine Wilms Tumor	Centre Oscar Lambret	P2	BB (68)
Irinotecan Wilms Tumor	Centre Oscar Lambret	P2	BB (66)
Cyclophosphamide Wilms Tumor	St. Jude Children's Research Hospital	P2	BB (65)
Etoposide Wilms Tumor	Centre Oscar Lambret	P2	BB (64)
Ipilimumab Wilms Tumor	Children's National Research Institute	P2	B (62)
Nivolumab Wilms Tumor	Children's National Research Institute	P2	B (57)
Olaparib Wilms Tumor	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Wilms Tumor	National Cancer Institute (NCI)	P2	B (57)
Tazemetostat Wilms Tumor	National Cancer Institute (NCI)	P2	B (57)
Vemurafenib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ensartinib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ivosidenib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Palbociclib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selinexor Wilms Tumor	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Selpercatinib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Fludarabine Wilms Tumor	St. Jude Children's Research Hospital	P1	CCC (50)
Onivyde Wilms Tumor	St. Jude Children's Research Hospital	P1/2	CCC (48)
Talazoparib Wilms Tumor	St. Jude Children's Research Hospital	P1/2	CCC (48)
Cis-Retinoic Acid Wilms Tumor	Centre Oscar Lambret	P1/2	CC (47)
Tegavivint Wilms Tumor	Children's Oncology Group	P1/2	CC (47)
Zoledronate Wilms Tumor	University of Florida	P1/2	CC (47)
Vorinostat Wilms Tumor	New York Medical College	P1	CC (46)
21.15.gpc3-car t cells Wilms Tumor	Baylor College of Medicine	P1	CC (43)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Wilms Tumor	Sun Yat-sen University	P1	CC (43)
b7-h3 car t cells Wilms Tumor	St. Jude Children's Research Hospital	P1	CC (43)
Care T Cells Wilms Tumor	Baylor College of Medicine	P1	CC (43)
Catch T Cells Wilms Tumor	Baylor College of Medicine	P1	CC (43)
Mesna Wilms Tumor	St. Jude Children's Research Hospital	P1	CC (43)
Pembrolizumab Wilms Tumor	Seattle Children's Hospital	P1	CC (43)
Sc-Car.Gpc3Xil15.21 Car T Cells Wilms Tumor	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr Wilms Tumor	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt Wilms Tumor	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg Wilms Tumor	Seattle Children's Hospital	P1	CC (43)
Cabozantinib Wilms Tumor	National Cancer Institute (NCI)	P2	NR ()